Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus ≥10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial

Table 3 Number of first transfusions occurring at hemoglobin ≤8 g/dL or > 8 g/dL

		Baseline Hemoglobin < 10 g/dL		Baseline Hemoglobin ≥10 g/dL
		Darbepoetin alfa 500 mcg Q3W	Darbepoetin alfa 2.25 mcg/kg QW	Darbepoetin alfa 500 mcg Q3W	Darbepoetin alfa 2.25 mcg/kg QW
First^a transfusion during week 5 to EOTP	Hb ≤8 g/dL, n (%)	30 (56)	29 (46)	12 (55)	12 (39)
	Hb > 8 g/dL, n (%)	24 (44)	34 (54)	10 (45)	19 (61)
First^a transfusion during week 1 to EOTP	Hb ≤8 g/dL, n (%)	42 (58)	30 (38)	9 (39)	14 (35)
	Hb > 8 g/dL, n (%)	30 (41)	48 (62)	14 (61)	24 (60)
	Hb missing, n (%)	1 (1)	0 (0)	0 (0)	2 (5)

Q3W = every three weeks; QW = weekly; EOTP = end of the treatment period (defined as the earlier of day 109 or end of study); Hb = hemoglobin; n = number of transfusion events. Note that as data described are for first transfusion only, n also equals the number of patients with at least one transfusion.
^aThe closest hemoglobin value on the day of transfusion or within 7 days prior was used.